Biotechnology

Astria Therapeutics

Astria Therapeutics Inc. Secures $400 Million in Loans for Merger with BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics for $700 Million

BioCryst Pharmaceuticals Plans to Merge with Astria Therapeutics

Astria Therapeutics released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 706 K (forecast USD 10.67 M), actual EPS USD -0.5455 (forecast USD -0.39)

Astria Therapeutics released FY2025 9 Months Earnings on November 12 (EST), actual revenue USD 706 K, actual EPS USD -1.6964

BioCryst Pharmaceuticals to Acquire Astria Therapeutics for $8.55 per Share and 0.59 Shares

BioCryst Pharmaceuticals Acquires Astria Therapeutics for Cash and Stock

Astria Therapeutics Launches Third-Stage Long-Term Trial of Navenibart for HAE

Clark-Gartner and H.C. Wainwright Recommend Buy on Astria Therapeutics Stock

Astria Therapeutics released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.57 (forecast USD -0.5866)

Astria Therapeutics released FY2025 Semi-Annual Earnings on August 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.1509 (forecast USD -1)

Astria Therapeutics to Present Navenibart Clinical Data at 2025 Hereditary Angioedema Association Summit

Astria Therapeutics Receives Nasdaq Incentive Allowance

Astria Therapeutics Announces Positive Clinical Trial Results for HAE Drug

Astria Therapeutics Holds Annual Shareholders Meeting

Astria Therapeutics Grants Stock Incentives According to Nasdaq Rules

Astria Therapeutics CEO to Participate in Jefferies Global Healthcare Conference

Astria Therapeutics Inc. to Discuss Navenibart Data at Symposium

Astria Therapeutics Displays navenibart Trial Results

Astria Therapeutics Inc Reports Widened Quarterly Loss Per Share

Agape ATP

Liminatus Pharma

Tradr 2X Long QBTS Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long RGTI Daily ETF

Wheeler Real Estate

NewGenIvf

Sunshine Biopharma

Co-Diagnostics

Infleqtion

ATXS

Ascletis Pharma Inc. has completed enrollment in its 13-week U.S. Phase II study of ASC30, an oral GLP-1R agonist for type 2 diabetes treatment. The study involves 100 participants and aims to evaluate the drug's efficacy, safety, and tolerability. Topline data is expected in Q3 2026. ASC30 is also being developed for obesity, with positive results from a previous study. The company anticipates FDA clearance for Phase III trials for obesity by late Q3 2026. Ascletis is focused on developing innovative therapeutics for metabolic diseases.

prnewswire

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

VG Health

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

SPDR S&P Biotech

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

ASCLETIS-B

20:10 ETAscletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes

NBSE.ESC

Egetis Therapeutics has appointed Tiago Nunes, MD, PhD, as Chief Medical Officer, effective May 1, 2026. Nunes, previously Senior VP at Mirum Pharmaceuticals, brings extensive experience in rare disease therapeutics. CEO Nicklas Westerholm expressed excitement about Nunes joining the team as they prepare for the U.S. launch of Emcitate® (tiratricol), the first treatment for MCT8 deficiency. Outgoing CMO Kristina Sjöblom Nygren will assist in the transition until Emcitate® is approved in the U.S. The company focuses on developing treatments for serious diseases with unmet medical needs.

MorningStar

ESC NEUBASE THERAPEUTI

Egetis Appoints Tiago Nunes as Chief Medical Officer

Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report

Tip Ranks

Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report

COSM

SBIO

Cosmos Health Inc. has appointed Dr. Dimitrios Iliopoulos, an expert in AI-driven drug discovery and clinical-stage biotechnology, to its Advisory Board. Dr. Iliopoulos, CEO of Athos Therapeutics, will support Cosmos Health's biotechnology initiatives. His extensive experience includes significant contributions to drug development for autoimmune diseases and cancer. CEO Greg Siokas emphasized that Dr. Iliopoulos's expertise will enhance the company's R&D efforts in high-value therapeutic areas. Cosmos Health is a diversified global healthcare group focused on pharmaceuticals, nutraceuticals, and innovative healthcare solutions.

StockTitan

Cosmos Health

SPDR S&P Health Equip

VanEck Pharmaceutical ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

SPDR Pharmac

ALPS Medical Breakthrough

Atossa Therapeutics

Invesco Pharmaceuticals ETF

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board | COSM Stock News

CS精准医

A recent study has provided valuable insights to assist business leaders in enhancing incentive design, inspiring field teams, and speeding up business results. Axtria Inc., a renowned global leader in AI-driven data analytics solutions for the life sciences industry, conducted the study. The findings were released on February 19, 2026, in Berkeley Heights, N.J. This study aims to assist commercial leaders in making data-informed decisions to drive success.

Unusual Whales

Axtria releases U.S. Incentive Compensation Benchmarking Study 2026 to aid life sciences, enhancing performance.

BCRX

BioCryst Pharmaceuticals Inc. (BCRX) shares have fallen over 40% from their 52-week high of $11.31, currently trading around $6. The company's main drug, ORLADEYO, has seen steady sales growth, reaching $326 million in 2023 and projected to hit $563 million in 2025. BioCryst aims for $1 billion in annual sales by 2029. The company also acquired Astria Therapeutics for $700 million to enhance its HAE portfolio. As of December 31, 2025, BioCryst's cash position was $338 million.

rttnews

Direxion S&P Biotech Bear 3X

BioCryst Pharma

Will BioCryst's ORLADEYO Hit The $1 Billion Sales Mark?

Astria Therapeutics(ATXS.US)

20:10 ETAscletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes

Egetis Appoints Tiago Nunes as Chief Medical Officer

Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board | COSM Stock News

Axtria releases U.S. Incentive Compensation Benchmarking Study 2026 to aid life sciences, enhancing performance.

Will BioCryst's ORLADEYO Hit The $1 Billion Sales Mark?